MX2021003156A - Tratamiento para la enfermedad del higado graso no alcoholico. - Google Patents

Tratamiento para la enfermedad del higado graso no alcoholico.

Info

Publication number
MX2021003156A
MX2021003156A MX2021003156A MX2021003156A MX2021003156A MX 2021003156 A MX2021003156 A MX 2021003156A MX 2021003156 A MX2021003156 A MX 2021003156A MX 2021003156 A MX2021003156 A MX 2021003156A MX 2021003156 A MX2021003156 A MX 2021003156A
Authority
MX
Mexico
Prior art keywords
liver disease
fatty liver
treatment
alcoholic fatty
nafld
Prior art date
Application number
MX2021003156A
Other languages
English (en)
Inventor
LI Chiang J
Zoltan Derdak
Jifeng Liu
Original Assignee
1 Globe Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1 Globe Biomedical Co Ltd filed Critical 1 Globe Biomedical Co Ltd
Publication of MX2021003156A publication Critical patent/MX2021003156A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona nuevos métodos para tratar o prevenir la enfermedad del hígado graso no alcohólico (EHGNA), incluida la esteatohepatitis no alcohólica (EHNA) en un mamífero, incluido un ser humano.
MX2021003156A 2018-09-18 2019-09-18 Tratamiento para la enfermedad del higado graso no alcoholico. MX2021003156A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862732644P 2018-09-18 2018-09-18
PCT/US2019/051790 WO2020061232A1 (en) 2018-09-18 2019-09-18 Treatment for non-alcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
MX2021003156A true MX2021003156A (es) 2021-05-14

Family

ID=69888816

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003156A MX2021003156A (es) 2018-09-18 2019-09-18 Tratamiento para la enfermedad del higado graso no alcoholico.

Country Status (12)

Country Link
US (1) US20220040172A1 (es)
EP (1) EP3852753A4 (es)
JP (1) JP2022501436A (es)
KR (1) KR20210079290A (es)
CN (1) CN112955143B (es)
AU (1) AU2019345297A1 (es)
BR (1) BR112021005086A2 (es)
CA (1) CA3113016A1 (es)
MX (1) MX2021003156A (es)
SG (1) SG11202102684VA (es)
TW (1) TWI825177B (es)
WO (1) WO2020061232A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049019A1 (en) 2016-09-07 2018-03-15 Temple University - Of The Commonwealth System Of Higher Education Compositions and methods for treatment of insulin resistance
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
TW202206062A (zh) * 2020-04-24 2022-02-16 美國坦普大學 高等教育聯邦系統 治療非酒精性脂肪肝炎的方法
US20230339871A1 (en) * 2020-08-18 2023-10-26 Metrea Biosciences, Inc. Compounds and methods of modulating 17b-hydroxysteroid dehydrogenase type 13

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2197878T (lt) * 2007-09-06 2016-09-26 Boston Biomedical, Inc. Kinazės inhibitorių kompozicijos ir jų panaudojimas vėžio ir kitų su kinazėmis susijusių ligų gydymui
US8889730B2 (en) * 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
BR112015022431A2 (pt) * 2013-03-13 2017-05-09 Boston Biomedical Inc derivados de 3-(aril ou heteroaril) metilenoindolin-2-ona como inibidores de quinases da via de sinalização de células-tronco cancerosas para o tratamento de câncer
JP6472096B2 (ja) * 2014-01-27 2019-02-20 ボストン バイオメディカル， インコーポレイテッド 癌を処置するための新規方法
WO2017026119A1 (ja) * 2015-08-10 2017-02-16 大日本住友製薬株式会社 ５－（チアゾール－４－イル）インドリン－２－オン誘導体の精製方法
CA3029596A1 (en) * 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
EP3852754A4 (en) * 2018-09-18 2022-06-15 1Globe Biomedical Co., Ltd. OBESITY TREATMENT

Also Published As

Publication number Publication date
EP3852753A4 (en) 2022-06-08
US20220040172A1 (en) 2022-02-10
TWI825177B (zh) 2023-12-11
CA3113016A1 (en) 2020-03-26
KR20210079290A (ko) 2021-06-29
WO2020061232A1 (en) 2020-03-26
SG11202102684VA (en) 2021-04-29
TW202034910A (zh) 2020-10-01
CN112955143B (zh) 2023-10-13
BR112021005086A2 (pt) 2021-06-08
CN112955143A (zh) 2021-06-11
EP3852753A1 (en) 2021-07-28
JP2022501436A (ja) 2022-01-06
AU2019345297A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
MX2021003156A (es) Tratamiento para la enfermedad del higado graso no alcoholico.
PH12017502359A1 (en) Glucagon and glp-1 co-agonist compounds
IL281093A (en) Combinations for the treatment of NASH/NAFLD and related diseases
EA201692050A1 (ru) Лечение неалкогольной жировой болезни печени и неалкогольного стеатогепатита
MX2019006864A (es) Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de factor de necrosis tumoral (tnf).
SA520412543B1 (ar) تركيبات وطرائق لعلاج السرطان والاضطرابات المناعية باستخدام جراثيم الفيونيلّة
MX2023003792A (es) Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
MX2021011949A (es) Metodos para el tratamiento de enfermedad de higado graso no alcoholico y/o lipodistrofia.
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
EP3710831A4 (en) MARKERS FOR THE DIAGNOSIS AND TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND ADVANCED HEPATIC FIBROSIS
IL266519A (en) Pharmaceutical use of a sustained-release preparation containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD/NASH)
MX2023007840A (es) Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
IL283200A (en) Combination for the treatment of NAFLD and NASH
PH12020500164A1 (en) Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
MX2021006784A (es) Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de estos.
MX2017012694A (es) Metodos para tratar la obesidad y la enfermedad del higado graso no alcoholica o esteatohepatitis no alcoholica utilizando anticuerpos antagonistas del receptor de glucagon.
IL284345A (en) Preparations and methods for the treatment of non-alcoholic fatty liver diseases
IL285989A (en) A method for treating fatty liver disease and/or fatty liver inflammation
EP3817749A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
MX2012012095A (es) Analogos de tiazolidinadiona.
EP3781158A4 (en) COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC FAT LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS
EP3827831A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
MX2019002579A (es) Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado.
EP3718552A4 (en) APPROPRIATE DRUG COMBINATION FOR THE TREATMENT AND PREVENTION OF NON-ALCOHOLIC HEPATIC STEATOSIS (NAFLAD) AND / OR NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND / OR HEPATIC STEATOSIS
MX2021001393A (es) Composiciones para el tratamiento de la enfermedad de injerto contra huesped.